Kiniksa Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results
LONDON, Feb. 19, 2026 – Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that it will host a conference call and live webcast on Tuesday, February 24, 2026, at 8:30 a.m. Eastern Time to report its fourth quarter and full year 2025 financial results and discuss recent portfolio developments.
Accessing the Webcast and Conference Call
A live webcast will be accessible through the Investors &. Media section of the company’s website at www.kiniksa.com. Individuals interested in participating in the call via telephone may register here. Upon registration, participants will receive a confirmation email detailing dial-in numbers and a unique passcode and registrant ID.
Replay Information
A replay of the event will be available on Kiniksa’s website within approximately 48 hours after the event.
About Kiniksa Pharmaceuticals
Kiniksa is a biopharmaceutical company focused on discovering, acquiring, developing, and commercializing novel therapies for diseases with unmet need, particularly in cardiovascular indications. Kiniksa’s portfolio is based on strong biologic rationale or validated mechanisms and offers potential for differentiation.
Investor & Media Contact
Jonathan Kirshenbaum
(781) 829-3949
jkirshenbaum@kiniksa.com
Related reading